SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (3695)6/23/1998 11:47:00 PM
From: James Baker  Read Replies (1) | Respond to of 9523
 
BigK,
The evidence is coming soon. Last week MUSE gains 6% in new RXs in a week that Viagra fell considerably. Viagra ia a great drug but is not the answer for everyone for both efficacy and contraindication reason. Our GOOD Urological friends will be SURE to tell and instruct these ED patients in the second best choice when Viagra isn't the one.
Jim



To: BigKNY3 who wrote (3695)6/23/1998 11:51:00 PM
From: James Baker  Respond to of 9523
 
Interesting note from practicing Urologist from the Vivus board, well worth reading regarding Viagra and Muse:

Message 4985981



To: BigKNY3 who wrote (3695)6/24/1998 7:26:00 AM
From: blankmind  Read Replies (1) | Respond to of 9523
 
"MUSE currently has a core base of 2,000-3,000 new Rxs per week down from an average of 12,500 in 1997."

- Okay, at first glance, you appear to be correct. But what about the fact that Astra & Jannssen are rolling MUSE out in 40 other countries? Can't the lost product be made up globally?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News